146
Participants
Start Date
July 31, 2015
Primary Completion Date
August 18, 2021
Study Completion Date
August 18, 2021
Enoblituzumab Schedule 1
enoblituzumab is administered by IV infusion once per week for up to 51 doses.
Pembrolizumab
Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
Enoblituzumab Schedule 2
Enoblituzumab is administered by IV infusion every 3 weeks for up to 17 doses
retifanlimab
Retifanlimab is administered by IV infusion every 3 weeks for up to 17 doses
Columbia University Medical Center, New York
Roswell Park Cancer Institute, Buffalo
University of Pittsburg, Pittsburgh
Hospital of the University of Pennsylvania/Abramson Cancer Center, Philadelphia
Christiana Care Health Services, Inc., Newark
University of Maryland Greenbaum Cancer Center, Baltimore
Greenville Health System, Greenville
Mayo Clinic - FL, Jacksonville
Moffitt Cancer Center, Tampa
Norton Cancer Institute Research Program, Louisville
Gabrail Cancer Institute, Canton
South Texas Accelerated Research Therapeutics, LLC - Midwest, Grand Rapids
Mayo Clinic - MN, Rochester
Nebraska Cancer Specialists, Omaha
Mary Crowley Cancer Research Center, Dallas
South Texas Accelerated Research Therapeutics, LLC, San Antonio
Mayo Clinic - AZ, Scottsdale
Comprehensive Cancer Centers of Nevada, Las Vegas
Dana-Farber Cancer Institute, Boston
Rhode Island Hospital, Providence
Lead Sponsor
MacroGenics
INDUSTRY